Results 151 to 160 of about 1,395,428 (175)

Breakthroughs of chimeric antigen receptor T-cell therapy in hematological malignancies: From <i>ex vivo</i> to <i>in vivo</i>. [PDF]

Chin J Cancer Res
Pei X, Du Y, Lyu M, Huang X.
europepmc   +1 more source

Virus-mediated gene fusion: igniting and sustaining oncogenesis. [PDF]

Trends Cancer
Starrett GJ.
europepmc   +1 more source

Understanding Basic Concepts of Viral Quasispecies: From Evolutionary Dynamics to Clinical Relevance. [PDF]

Pathogens
Rodríguez-Frías F, Oubiña JR, Tabernero D, Cortese MF, Gregori J, Buti M, Rando-Segura A, Quer J.   +7 more
europepmc   +1 more source

Ancestral reconstruction supports that loss of Nef-mediated T cell modulation coincided with the emergence of pathogenic lentiviruses. [PDF]

J Virol
Baldino AM, Mumby MJ, Edgar CR, Olabode AS, Poon AFY, Dikeakos JD.   +5 more
europepmc   +1 more source

Targeted IL-27-based gene therapy in preventing SARS-CoV-2 entry. [PDF]

Mol Biol Rep
Mulia GE, Salameh JW, Figueiredo ML.
europepmc   +1 more source

Vaccination with an HSV-1 virus containing CD-137L reduces herpetic corneal disease when used both prophylactically and therapeutically. [PDF]

Virus Res
Stuart PM, Yin ZT.
europepmc   +1 more source

HCV-specific CD4⁺ T-cells are susceptible to HIV-1 and contribute to viral persistence during antiretroviral therapy. [PDF]

EBioMedicine
Gobran ST, Ortiz AE, Khedr O, Dion J, Raymond Marchand L, Dias J, Cattin A, Bruneau J, Chomont N, Klein MB, Ancuta P, Shoukry NH.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

Vaccine, 2021
Hanneke Schuitemaker, Robert T. Chen, Jerome Custers   +2 more
exaly